Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enfortumab vedotin + pembrolizumab + carboplatin
- Development stage
- Unknown
- Lead developer
- Astellas Pharma
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This is a **combination regimen** used for the treatment of locally advanced or metastatic urothelial carcinoma in patients eligible for platinum-based chemotherapy. It consists of: - **Enfortumab vedotin**: an antibody-drug conjugate (ADC) targeting Nectin-4, conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting agent. Combines targeted cytotoxic delivery with the mechanism of the antibody binding specifically to Nectin-4 expressing tumor cells, leading to cell death. - **Pembrolizumab**: a programmed death 1 (**PD-1**) immune checkpoint inhibitor, fostering an immune response against tumor cells by blocking PD-L1 and PD-L2 interaction. - **Carboplatin**: a platinum-based chemotherapy agent that causes DNA crosslinking and apoptosis in rapidly dividing cells. This regimen is used primarily as a first-line therapy for advanced or metastatic urothelial carcinoma, especially in patients unsuitable for cisplatin[1][5][7]. The combination leverages both targeted immunotherapy and cytotoxic effects and is associated with a statistically significant survival benefit as compared to platinum chemotherapy alone[1][5][7].
- Brand names
- PADCEV (enfortumab vedotin)KEYTRUDA (pembrolizumab)None (carboplatin is typically generic)
02
Targets
TUBB (Tubulin (alpha and beta subunits))PVRL4 (Nectin cell adhesion molecule 4)PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on enfortumab vedotin + pembrolizumab + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enfortumab vedotin + pembrolizumab + carboplatin.